A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

NCT01047579 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rivastigmine transdermal

Sponsor

Novartis Pharmaceuticals